Myeloproliferative disorders (MPD) are chronic tumoral diseases of the bone marrow characterised by the primary involvement of the stem cell leading to the proliferation of myeloid cells. The various disease entities are secondary to the type of proliferating cells : erythrocytes for polycythemia vera (PV), platelets for essential thrombocythemia (TE) and granulocytes for chronic myeloid leukemia (CML). For idiopathic myelofibrosis (IM), the progressive accumulation of bone marow fibers is secondary to the involvement of megakaryocytes, the progenitor cells of thrombocytes.
During the last 10 years the natural history of CML, the most aggressive form of MPD, has been substantially improved by the discovery and therapeutic use of tyrosine kinases inhibitors. Other forms of MPD's, however, and in particular IM, do not benefit from this improvement and still remain a therapeutic challenge for scientists and clinicians. The recent discovery of a recurrent molecular mutation (JAK-2) in the cells of most of the others MPD's has open new perspectives for the therapy of these diseases.
The JGGF goal in the field of haematology is the support of basic and applied research on MPD's other than CML. Support will be granted to scientific or medical post-doctoral fellow to develop high quality research in institutions internationally renowned in this field. Initial grants will cover 2 years but can be prolonged if necessary.
Application deadline: Tbd